CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues	$ 29,378	$ 27,872	$ 57,609	$ 54,152
Operating expenses:
Research and development	60,019	60,086	118,603	116,520
General and administrative	15,093	16,486	30,001	32,634
Total operating expenses	75,112	76,572	148,604	149,154
Loss from operations	(45,734)	(48,700)	(90,995)	(95,002)
Interest and other income, net	2,643	1,550	3,985	2,176
Loss before income taxes	(43,091)	(47,150)	(87,010)	(92,826)
Income tax expense	82	24	140	287
Net loss	(43,173)	(47,174)	(87,150)	(93,113)
Net loss attributable to non-controlling interest	0	(5)	0	(11)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders, basic	(43,173)	(47,169)	(87,150)	(93,102)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders, diluted	$ (43,173)	$ (47,169)	$ (87,150)	$ (93,102)
Earnings per share, basic (in dollars per share)	$ (0.29)	$ (0.33)	$ (0.59)	$ (0.65)
Earnings per share, diluted (in dollars per share)	$ (0.29)	$ (0.33)	$ (0.59)	$ (0.65)
Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	148,158	143,984	147,194	143,550
Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	148,158	143,984	147,194	143,550